Gilead Sciences (NASDAQ:GILD) initiated with Market Perform rating by Oppenheimer. Shares up a fraction premarket.
FibroGen (NASDAQ:FGEN) initiated with Neutral rating and $61 (2% upside) price target by Mizuho Securities.
Akebia Therapeutics (NASDAQ:AKBA) initiated with Buy rating and $24 (25% upside) price target by Mizuho.
Aptevo Therapeutics (NASDAQ:APVO) resumed with Overweight rating and $6 (159% upside) price target by Piper Jaffray. Shares up 24% premarket.
Biogen (NASDAQ:BIIB) upgraded to Overweight by Morgan Stanley. Shares up 2% premarket.
AmerisourceBergen (NYSE:ABC) upgraded to Outperform with a $96 (16% upside) price target by Robert W. Baird. Shares up 3% premarket.
Celgene (NASDAQ:CELG) downgraded to Underweight by Morgan Stanley citing looming generic threat to Revlimid. Shares down 3% premarket.
Mallinckrodt (NYSE:MNK) downgraded to Hold by Canaccord Genuity. Shares down 4% premarket.
Diplomat Pharmacy (NYSE:DPLO) price target raised to $23.75 (12% upside) following its acquisition of 8th Day Software.
Premarket analyst action – healthcare – AmerisourceBergen Corporation (NYSE:ABC)